Briacell Therapeutics Corp BCTX

$4.28 +0.20 (4.90%)

Valuation

Market cap
35,495,000
Revenue TTM
$0
Net income TTM
$-26,310,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
90,200
Avg volume
324,008
Day's range
$4.01 – $4.34
Shares out
8,700,000
Stochastic %K
70%
Beta
1.10
Analysts
Strong Buy
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 921 1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

Biotechlineup Oct 1, 10:25 AM
$BCTX Let’s recap. The hockey stick enrollment wave means the trial is closing. For me I’m convinced it’s no longer If. operational burn is dropping, and the 2nd qtr 2027 cash runway securely steps over the December finish line with no dilution threat. The P=0.0009 historical correlation, majority of Phase 3 patients are showing positive DHT skin responses, proves the drug is actively turning on the immune system in the treatment arm. The control arm with a Hockey stick enrollment is carrying the entire weight of the 144 death milestone right now due to that surge, setting up statistical divergence at unblinding. The unknown of course is the .6 Hazzard Ratio interim read out . IMO .7 HR means a 30% reduction in mortality with virtually no side effects means a FDA approval and guaranteed partnership.
1 replies
Biotechlineup Oct 1, 10:01 AM
$BCTX HOCKEY STICK!! The clue ! When I just ran a Monte Carlo . <>Because the drug works too well (the high DHT+ group stays alive), a standard sample size only has a 5.7% probability of hitting 144 deaths by December.>> I’m so sure of this now. What they are missing is the enrollment they previously were having has gone hockey stick. Flat to a massive increase and Enrollment Shock wave. Means The Control Arm number has increased and that’s the Variable that needs to be plugged into any Monte Carlo simulation. If you do that the predictably of Control arm deaths easily crosses the December timeframe with a 98% timeline by December. Management literally states that they have hit the vertical part of the curve and are skipping minor updates because the trial is imminently closing to full enrollment. That’s why they are so confident in the 2nd qtr cash runway. Once the trial is over (full enrollment) there expenses drop dramatically. AI 5.8% to 98% . AI was impressed .
1 replies
Juhanialainen Oct 1, 4:12 AM
$VERA $CING $MAIA $BCTX $PYPD We are soft launching a comprehensive one-solution-to-cover-all-needs biotech investing service powerhouse — http://bioradar.io. This is BIG! The monthly price is insanely cheap, at least for now and you’ll get free 7 day trial to test it out risk free. I’m a partner in this 🇫🇮 based service as a Brand Ambassador & Senior Advisor and been involved in developing this service for the last few months in silence. Now the service is ready. We’ve built dozens of APIs to major data sources like Edgar for example for SEC filings, we have built-in PDUFA date calendar, dilution tracking, company cash situation, price volatility and social buzz alerts directly into your email and dozens of other features that a biotech investor needs. All in one place with just a few dollars per month. Check it out, try it free and let me know what you think?
1 replies
EscapePlan Oct 1, 12:37 AM
$BCTX according to our AI friend, if we hit the 144 event in December a Monte Carlo simulation shows probability of success (hr<0.6) is virtually zero, if it hits in January it’s around 38% and February it’s around 78%. In sunnary, we really don’t want to hit this situation until next year, otherwise it’s highly probable that this will need to run through the full phase 3 and so we will require another sizable capital raise. If it’s going to take up to two months for the readout, then we should be hoping that we don’t hear anything until lateQ1 or even April next year. Just saying. We really don’t want to get anything this year - question is whether the share price runs up in advance of the readout, or if it runs out of steam and fear starts creeping as we head into 2027….
4 replies
AliceFireSteam Sep 30, 7:12 PM
$BCTX posted the other txt that we got fyi
0 replies
Biotechlineup Sep 30, 6:34 PM
$BCTX Pre Super Golden Cross screaming . Finally starting to fire up. The replay of the roadshow is up, probably printed into transcript and being run through AI right now. Still early. Cho Cho train ready to leave.
0 replies
AliceFireSteam Sep 30, 4:42 PM
$BCTX can't post any links, very weird
1 replies
smallpower17 Sep 30, 3:17 PM
$OSTX $BCTX For my friends in OSTX and BCTX, you might also want to take a look at $SCYX It also has some exciting 2026 catalysts and a ton of upside.
0 replies